Zenas BioPharma, Inc.
ZBIO$1.90B
Small CapNASDAQBiotechnology🇺🇸North America130 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Jun 15, 2026
16wMarket Overview
Stock performance and key metrics
ZBIO News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Obexelimab
IgG4 Related Disease
Orelabrutinib
Multiple Sclerosis (MS) Primary Progressive
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Obexelimab | Phase 3 | IgG4 Related Disease | - |
Orelabrutinib | Phase 3 | Multiple Sclerosis (MS) Primary Progressive | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply